bullish
QUICKNOTE: H1 Results in Line, R&D Pipeline Expands
271 Views24 Sep 2015 05:01
3SBio, China's leading biotech company, posted H1 results in line with pre-deal expectations. The recent acquisition of Zhejiang Wansheng broadens...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
Price Chart(Sign Up to Access)
- QUICKNOTE: H1 Results in Line, R&D Pipeline Expands24 Sep 2015
- A Leading Chinese Biotech Company, Quality Cornerstones, Take the Deal29 May 2015
x